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Aim: Anoxic brain injury (ABI) due to non-fatal drowning may cause persistent
vegetative state (VS) that is currently incurable. The aim of this paper is to present the
safety and feasibility of autologous bone marrow-derived mononuclear cell (BMMNC)
transplantation in five drowning children surviving in persistent VS.
Methods: We used BMMNC as a novel candidate therapeutic tool in a pilot phase-I
study for five patients affected by neurological sequelae after near-death drowning.
Autologous BMMNCs were freshly isolated using Ficoll gradient centrifugation then
infused intrathecally to five patients. The number of transplantation varied from two to
four times depending on the motor function improvement of patient after transplantation.
Clinical therapeutic effects were evaluated using gross motor function measure and
muscle spasticity rating scales, cognitive assessments, and brain MRI before and after
cell administrations.
Results: Six months after BMMNC transplantation, no serious complications or
adverse events were reported. All five patients displayed improvement across the major
parameters of gross motor function, cognition, and muscle spasticity. Three patients
displayed improved communication including the expression of words. In particular, one
patient remarkably reduced cerebral atrophy, with nearly normal cerebral parenchyma
after BMMNC transplantation.
Conclusions: Autologous BMMNC transplantation for the treatment of children in
persistent VS after drowning is safe, feasible, and can potentially improve motor function
and cognition and reducemuscle spasticity. These results pave the way for a future phase
II clinical trial to evaluate the efficacy of the therapy.
Keywords: drowning, persistent vegetative state, bone marrow mononuclear cells, autologous, cell therapy
Liem et al. BMMNC for Drowning
INTRODUCTION
Drowning is a major cause of mortality and neurological
morbidity worldwide, accounting for 370,000 annual deaths in
2012 (1). Children aged 0–14 years are especially susceptible
with over 450 children dying and thousands more suffering
debilitating injuries every day due to drowning globally (2).
For those children who survived drowning, anoxic brain injury
(ABI)-induced neurological morbidity is a common outcome due
to oxygen deprivation (3, 4). At least 5% of children admitted
for drowning suffered from a severe neurological deficit, with
outcomes of functional disability to vegetative states (VS) (2, 5).
From a pathological point of view, non-fatal drowning ABI
involves a complex accumulation of brain injuries due to
ischemia, hypoxia, cytotoxicity, and combinations thereof (6).
These insults deprive the brain not only of oxygen but also
of glucose and other nutrients required for neural metabolism.
In severe non-fatal drowning incidents, the deprivation of
these neural supporting supplements could trigger severe
motor nerve deficits that largely underlie serious physical,
cognitive, and behavioral complications (7). In these patients,
quadriplegia resembling severe cerebral palsy is the most
common consequence. Such morbidities cause a severe lifelong
impact not only on the patients’ health and well-being but
also on their family (1), whereas no effective treatment is
currently available.
There has been growing evidence of safety and benefit of
autologous bone marrow-derived mononuclear cells (BMMNCs)
in patients with a variety of neurological damage conditions (8–
14). BMMNCs are a heterogeneous group of cells consisting of
a small proportion of progenitor cells, such as hematopoietic
stem cells (HSCs), mesenchymal stem cells (MSCs), MUSE cells,
and endothelial progenitor cells that could potentially produce
synergic effect promoting neuronal protection and regeneration
and functional recovery.
Several characteristics make BMMNCs an attractive candidate
for the management of VS. In animal models, there is evidence
that transplanted BMMNCs cross the blood–brain barrier
(15) and exert long-term neuroprotection by accelerating
neuroplasticity and facilitating neuronal regeneration and
functional recovery (16–19). In addition, they can promote
endogenous neural stem cell (NSC) proliferation (20).
Furthermore, high levels of growth factors, cytokines, and
extracellular matrix molecules produced by BMMNCs could
have potential neurotrophic or neuroprotective effects in the
injured brain (21). Mesenchymal stem cells (MSCs), although
representing a small fraction in BMMNCs, have been shown
to differentiate into neuron-like cells and glial cells (22–25),
whereby accelerating neuroplasticity, promoting neuronal
regeneration and functional recovery, and enhancing the
proliferation of endogenous neuronal stem cells (16–20). In
Abbreviations: ABI, Anoxic brain injury; BMMSC, Bone marrow-derived
mesenchymal stem cell; BMMNC, Bone marrow-derived mononuclear cell; CRS,
Coma remission scale; EGG, Electroencephalogram; HSC, Hematopoietic stem
cell; MRI, Magnetic resonance imaging; MSC, Mesenchymal stem cell; PBS,
Phosphate-buffered saline; VS, Vegetative state; NSC, Neural stem cell.
addition, the presence of both MSCs and hematopoietic stem
cells (HSCs) in BMMNCs could potentially produce a better
and synergic effect as compared with each individual cell type
(12–14). Besides, BMMNCs also contain MUSE cells that
may contribute to neural cell regeneration and functional
recovery (26–28).
In humans, we and others recently demonstrated the safety
and feasibility of BMMNC transplantation in patients with a
variety of neurological damage conditions such as traumatic
brain injury (29, 30), cerebral hemorrhage (9), stroke (31–
34), spinal cord injury (10, 11), cerebral palsy (12), and
autism (13, 14). These encouraging results in combination
with the neuroplasticity of the childhood brain provide a great
opportunity for the stem cell-based treatment of pediatric non-
fatal drowning ABI. The aim of this report is to present the safety
and effectiveness of autologous BMMNC transplantation in five
drowning children surviving in persistent VS.
PATIENTS AND METHODS
Patient’s Enrollment
We conducted a prospective case series using data collected from
Vinmec International Hospital in Hanoi, Vietnam. The study
was approved by the Hospital Board of Vinmec International
Hospital. Five consecutive children with neurological sequelea,
due to a near-death drowning incident were enrolled in this
study. Clinical data was collected from January 2016 through
December 2018. Following presentation of the Study Information
Sheet, the participants’ guardian(s) were made fully aware of
the aim of the study and any potential side-effects before
being invited to consider participant enrolment by signing the
informed consent according to Good Clinical Practice and the
Helsinki Declaration.
The general data collected before the transplantation consisted
of age, gender, health condition prior to the accident, clinical
findings concerning cognition, motor function, and muscle
tone. All patients underwent neuroimaging assessments pre- and
posttransplantation, using brain magnetic resonance imaging
(MRI) on a 3-Tesla MRI device (Skyra Siemens, Germany)
with the following sequence: axial T2W, FLAIR, IR, diffusion,
ADCmap, coronal T2W, and sagittal T1W.
Autologous BMMNC Collection, Isolation,
and Transplantation
Autologous bone marrow was aspirated through an anterior iliac
crest puncture under general anesthesia in the operating theater.
The volume collected was in correlation with the patients’ body
weight, 8 ml/kg for patients under 10 kg [80ml + (body weight
in kg−10)× 7ml] for patients above 10 kg (21).
Mononuclear cells were isolated from aspirated bone marrow
by gradient centrifugation using Ficoll-Paque (GE Healthcare,
Sweden) in a clean room following ISO 14644 standard at
Vinmec Research Institute of Stem Cell and Gene Technology.
The cell suspension was washed with phosphate-buffered saline
(PBS) solution and resuspended in autologous plasma to a total
volume of 10ml for injection. The sterility of the product was
confirmed by microbiological evaluation via the BacT/Alert R©
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3D microbial detection system (Biomerieux, USA). Total blood
components before and after Ficoll-Plaque separation were
evaluated by Beckman Coulter LH780 hemacytometer. The
hematopoietic stem cell content (CD34+ cells) was assessed
according to the International Society of Hematotherapy and
Graft Engineering guideline (ISHAGE guideline) using Stem-
KitTM Reagent, Beckman Coulter in Navios flow cytometer.
Before injection, cell products were examined for endotoxin
levels with the Endosafe-PTS kit (Charles River).
Collected BMMNCs were infused intrathecally between the
4th and 5th lumbar vertebrae over the course of 30min using
an electrical pump, through a 22-gauge spinal needle. Each
patient received a minimum of two times and maximum of
four times of transplantations 6 months apart depending on his
motor function improvement after transplantation. The number
of BMMNCs that we collected each time is described in Table 1,
and all the collected cells were used for transplantation. Based
on our previous studies showing that BMMNC transplantation
led to markedly improved gross motor function in patients
with neurological complications such as cerebral palsy (12, 35)
and neurological sequelae due to intracranial hemorrhage (36),
the ability of patient to sit up was selected as satisfactory
criteria to evaluate if the patient needs additional transplantation.
If the patient could not show the improvement as indicated
by their ability to sit up after BMMNC transplantation,
additional transplantation will be implemented but not more
than four times.
After transplantation, physiotherapy by takingmotor function
exercises using motor-facilitation techniques was given to all the
patient 2 h/day for 12 days at the hospital and then continued
at home.
Safety Evaluation
Adverse events were graded during and after BMMNC
administration according to the NIH Common Terminology
Criteria for Adverse Events (CTCAE), version 4 (https://ctep.
cancer.gov/).
Efficacy Assessment
To evaluate the efficacy of BMMNC therapy, the muscular
spasticity [Modified Ashworth Scale (MMAS)] (26), gross motor
function (GMFM-88) (27), Denver II (Denver Developmental
Screening Test) for neurological assessment (28), and German
Coma Remission Scale (37) were measured before and at 6 and
12 months after transplantation. All patients were evaluated at
admission and followed up after transplantations by a qualified
rehabilitation specialist.
Case Presentation
Case 1
A previous healthy 23-month-old male suffered from drowning
with an estimated submersion period of 5min. After drowning,
he required a ventilator for 1 week. The duration from drowning
to stem cell transplantation was 3 months. Before the accident,
he could speak, run, and had good communication. After the
accident, he had no awareness, no motor function, and exhibited
muscle spasticity. Examination on 28th December 2016 when he
was 26 months old showed a vegetative status with tetraplegia
and generalized muscle spasticity of level V (Figure 1A). Total
coma remission scale (CRS) was 5 points (Table 2) including
arousability/attention of 1 point, motoric response of 1 point,
response to acoustic stimuli of 0 point, response to visual stimuli
of 1 point, response to tactile stimuli of 1 point, and logomotor
(speech motoric) response of 1 point. Brain MRI demonstrated
diffuse cerebral atrophy at the supratentorial and infratentorial
regions and abnormal signal (increased signal intensity) at the
bilateral cortical parietal lobe and bilateral putamen (Figure 1B).
The patient underwent three BMMNC transplantations
without any adverse events. Cellular information is presented
in Table 1.
TABLE 1 | General characteristics of the study participants at initial evaluation.
Case Gender Age at transplantation
(months)
Disease duration
(months)
Modified ashworth
scale
Transplantation BMMNC
(x 106)/kg
CD34
(x 106)/kg
1 M 26 3 4 1st 29.2 3.7
2nd 38.2 5.3
3rd 22.6 2.8
2 M 36 13 4–5 1st 10.9 0.6
2nd 7.2 0.4
3rd 24.6 1.3
4th 18.8 1.2
3 M 63 4 5 1st 13.4 0.6
2nd 33.5 5.5
3rd 17.3 1.4
4 M 37 9 3–4 1st 33.8 7.6
2nd 39.4 3.6
3rd 87 5.0
5 M 25 2.5 4–5 1st 19.3 2.4
2nd 52.3 4.4
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FIGURE 1 | The patient (case 1) before and after autologous bone marrow-derived mononuclear cell (BMMNC) transplantation. (A) The patient before BMMNC
transplantation is in a VS 3 months after the drowning. He had no awareness, no motor function, and exhibited muscle spasticity at level V. (B) Brain MRI
demonstrated diffuse cerebral atrophy (arrows) at supratentorial and infratentorial regions, abnormal signal intensity at bilateral cortical parietal lobe, and bilateral
putamen. (C) Six months after the third transplantation, the patient could express his need by vocalization, smile during communication, and stand. (D) No abnormal
signal at bilateral cortical parietal lobe and bilateral putamen was observed at 12 months after the third transplantation.
TABLE 2 | Summary of clinical parameters of our five-patient cohort.
Case Motor function after
the last transplantation
Cognition after the
last transplantation
Changes of
muscle spasticity
Coma remission scale
Before transplantation After the last transplantation
1 Sit up Speak Levels V to I 5 22
2 Turn Express emotions Levels V to II 4 20
3 Sit up Express emotions Levels V to III 8 24
4 Sit up and crawl Speak Levels IV to I 6 22
5 Sit up Speak Levels V to II 3 15
Progress after transplantations
Improvements of cognition, motor functions, and muscle
tonus were observed after each transplantation. Following
on from the first transplantation, he could express emotion
during communication, make some sounds, and turn.
Total CRS increased to 15 points including 3 points in
arousability/attention, 4 points in motoric response, 2 points in
response to acoustic, 2 points in response to visual stimuli, 2
points in response to tactile stimuli, and 2 points in logomotor
(speech motoric) response. The second transplantation saw
improvements in response to sound and light, eye movement in
response to objects, and sitting with support. Total CRS increased
to 19 points including 4 points in arousability/attention, 5 points
in motoric response, 3 points in response to acoustic stimuli, 3
points in response to visual stimuli, 2 points in response to tactile
stimuli, and 2 points in logomotor (speech motoric) response.
The third transplantation resulted in an ability to express
his need by vocalization, to smile during communication, and
to stand without support (Figure 1C). Muscle spasticity was
reduced from level V to level I after three transplantations. Total
CRS increased to 22 points (Table 2).
A brain MRI taken on 11th January 2018 (12 months after the
first transplantation) showed that diffuse cerebral atrophy at the
supratentorial and infratentorial regions still existed. However,
there was no abnormal signal at the bilateral cortical parietal lobe
and bilateral putamen (Figure 1D).
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Case 2
Case 2, a male, born on 27th January 2013, suffered from
drowning at 23 months old. His estimated duration in the
water was approximately 10min. After drowning, he required a
ventilator for 7 weeks. The duration from drowning to BMMNC
transplantation was 13 months. Before drowning, he could
speak, understand, walk, run, and had good communication.
After drowning, he lost his awareness and motor function.
Examination on 25th January 2016, when he was 36 months old,
confirmed his vegetative status: no awareness, nomotor function,
and generalized muscle spasticity at level V (Figure 2A).
Total CRS was only 4 points (Table 2) including 1 point in
arousability/attention, 1 point in motoric response, 1 point in
response to acoustic stimuli, 0 point in response to visual stimuli,
0 point in response to tactile stimuli, and 1 point in logomotor
(speech motoric) response. Brain MRI showed diffuse cerebral
atrophy at the supratentorial region and abnormal signal at the
bilateral putamen (Figure 2B).
The patient underwent four BMMNC transplantations with
cellular information as presented in Table 1. No adverse effects
were observed. After discharge, a standard physiotherapy
regimen was applied as described for patient 1.
Progress after transplantations
After transplantations, improvements of cognition were
observed. Emotional expression when being called was noted
after the first transplantation and cognition continued to
improve progressively. Initial improvement of total CRS was
noted with an increase of total score to 10 points including 2
points in arousability/attention, 3 points in motoric response,
1 point in response to acoustic stimuli, 1 point in response to
visual stimuli, 2 points in response to tactile stimuli, and 1 point
in logomotor (speech motoric) response.
Following on from the fourth transplantation, he could
respond to sound and music and could smile or cry during
communication. Improvement in motor function was also
observed. After four transplantations, he could turn and could lift
his head up when lying prone (Figure 2C). Muscle spasticity was
reduced from level V to level II. Total CRS reached to 20 points
(Table 2) including 4 points in arousability/attention, 5 points
in motoric response, 3 points in response to acoustic stimuli, 3
points in response to visual stimuli, 3 points in response to tactile
stimuli, and 2 points in logomotor (speech motoric) response.
Brain MRI taken on 16th December 2017 (23 months after
the first transplantation) showed no significant change when
FIGURE 2 | The patient (case 2) before and after autologous BMMNC transplantation. (A) Thirteen months after the drowning before BMMNC transplantation, the
patient is in a VS without awareness, no motor function, and exhibited muscle spasticity at level V. (B) Diffuse cerebral atrophy at supratentorial region and abnormal
signal at bilateral putamen on brain MRI before transplantation (arrows). (C) Six months after the fourth transplantation, the patient could respond to sound and music,
smile or cry during communication, and turn and lift his head up when lying prone. (D) However, there was no significant change in brain MRI after transplantations in
comparison with that before transplantation.
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compared with the MRI findings before the transplantation
(Figure 2D).
Case 3
Case 3, a male, born on 26thMarch 2011, suffered from drowning
at 59 months old. His estimated duration in the water was
∼5min. After cardiopulmonary resuscitation, he required a
ventilator for 5 weeks. The duration from drowning to the first
transplantation was 4 months.
Prior to the accident, his cognition, communication and
motor function had developed normally. Examination on 3rd
May 2016, when he was 63 months, revealed that the child had
no awareness and suffered from quadriplegia and generalized
muscle spasticity at level V, causing an abnormal posture of the
body, legs, feet, hands, and forearm (Figure 3A). Total CRS was 8
points (Table 2) with 2 points in arousability/attention, 2 points
in motoric response, 1 point in response to acoustic stimuli, 1
point in response to visual stimuli, 1 point in response to tactile
stimuli, and 1 point in logomotor (speech motoric) response.
Epilepsy occurred more than 10 times/day, and its treatment
required 500mg of Keppra and 200mg of Depakin daily.
Brain MRI showed diffused cerebral atrophy at the
supratentorial and infratentorial regions (Figure 3B). His
electroencephalogram (EEG) showed diffused epileptic waives.
The child received three transplantations at 63, 69, and 76
months of age, without any adverse effects. Cell details are
presented in Table 1.
Progress after transplantation
After three transplantations, cognition was significantly
improved, the child responded to calling, recognized objects,
expressed need, expressed feelings (such as happiness or sadness),
and watched TV. During the last examination, he could reach
a maximal CRS of 24/24 points (Table 2) including 5 points in
arousability/attention, 6 points in motoric response, 3 points
in response to acoustic stimuli, 4 points in response to visual
stimuli, 3 points in response to tactile stimuli, and 3 points in
logomotor (speech motoric) response. Muscle spasticity reduced
from level V to level III. The child could also sit up (Figure 3C)
with no manifestation of epilepsy; however, medication with
Keppra was still maintained at 500 mg/day.
Brain MRI result shows that cerebral atrophy was reduced
remarkably compared with the brainMRI before transplantation,
with nearly normal cerebral parenchyma (Figure 3D).
Case 4
Case 4, a male, born on 26th July 2013, suffered from drowning at
28 months old. His estimated time in the water was∼10min. He
required a ventilator for 10 days. The duration from drowning to
stem cell transplantation was 9 months.
FIGURE 3 | The patient (case 3) before and after autologous BMMNC transplantation. (A) The patient before BMMNC transplantation is in a VS 4 months after the
drowning. He had no awareness and suffered from quadriplegia with muscle spasticity at level V. (B) Diffuse cerebral atrophy at the supratentorial and infratentorial
regions on brain MRI before transplantation (arrows). (C) Six months after the third transplantation, the patient could respond to calling, recognized objects, sit up, and
expressed feelings. (D) Brain MRI showed a remarkably reduced cerebral atrophy with near-normal cerebral parenchyma (arrows) after stem cell transplantation.
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Before the accident, the child attended nursery school. He
could speak and sing simple songs, and his motor function and
communication had developed normally. At examination on
16th August 2016, before the transplantation when he was 37
months old, his social interaction was equivalent to a child at
3 months of age. He could not recognize his parents, had no
reaction during communication, could not follow objects, and
he could not speak. Total CRS was 6 points (Table 2) as follows:
1 point in arousability/attention, 1 point in motoric response,
1 point in response to acoustic stimuli, 1 point in response to
visual stimuli, 1 point in response to tactile stimuli, and 1 point
in logomotor (speech motoric) response. He could turn while
lying on the floor but could not sit up or crawl (Figure 4A).
Muscle spasticity was assessed at level IV. Epilepsy occurred and
he required 100mg of Depakin, 1–2 times/day.
Brain MRI on 6th July revealed a diffused cerebral atrophy
(Figure 4B). EEG revealed diffused epileptic waves.
He received three BMMNC transplantations at the age of
37, 43, and 49 months (Table 1), respectively, without any
adverse events.
Progress after transplantations
Improvements in cognition, motor function, and muscle
spasticity were manifested after transplantations. Cognition
improved progressively. He could recognize his parents, smile
during communication, and make some sounds, subsequent
to the last transplantation. The last examination revealed that
total CRS was 22 points (Table 2) including 4 points in
arousability/attention, 5 points in motoric response, 3 points
in response to acoustic stimuli, 4 points in response to visual
stimuli, 3 points in response to tactile stimuli, and 3 points
in logomotor (speech motoric) response. His motor function
also improved. After the first transplantation, the patient could
sit up with support. He could sit without support and could
crawl after the second transplantation, and eventually could stand
with support following the last transplantation (Figure 4C).
Muscle spasticity reduced from level IV to level I after the
transplantations. Epilepsy no longer occurred after the first
transplantation. Medication with Depakin was gradually reduced
and eventually suspended without recurrence of epilepsy.
Brain MRI taken on 24th October 2017 showed no
significant changes compared with the findings before the
first transplantation (Figure 4D).
Case 5
Case 5, amale, born on 18th August2015, suffered from drowning
at the age of 23 months. His estimated duration in the water was
approximately 5min. After drowning, he required a ventilator for
7 days. The duration from drowning to stem cell transplantation
was 2.5 months.
FIGURE 4 | The patient (case 4) before and after autologous BMMNC transplantation. (A) Nine months after the drowning before BMMNC transplantation, the patient
had no reaction during communication and could not follow objects and speak and exhibited muscle spasticity at level V. He could not sit up or crawl and had
epilepsy. (B) Brain MRI revealed diffuse cerebral atrophy before transplantation (arrows). (C) Six months after the third transplantation, the patient’s cognition improved
progressively and could stand with support. (D) However, brain MRI showed no significant change after transplantations.
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Prior to drowning, he had started to speak and had normal
motor function and cognition. Examination on 25th September
2017, when he was 25.5 months old, confirmed a vegetative
status. There was no awareness or motor function, and the
child had tetraplegia and generalized muscle spasticity at level
V (Figure 5A). Total CRS was only 3 points (Table 2) with
arousability/attention of 0 point, motoric response of 1 point,
response to acoustic stimuli of 0 point, response to tactile stimuli
of 1 point, and logomotor (speech motoric) response of 1 point.
Brain MRI on 23rd August 2017 showed a diffuse brain
atrophy and abnormal signal at the bilateral putamen
(Figure 5B).
He underwent two BMMNC transplantations at 25 and
32 months without any adverse events. Details about the
transplanted cells are presented in Table 1.
Progress after transplantation
The first transplantation resulted in a capacity to respond to
sounds and voices. Total CRS increased to 10 points including
2 points in arousability/attention, 3 points in motoric response,
2 points in response to acoustic stimuli, 1 point in response
to visual stimuli, 1 point in response to tactile stimuli, and 1
point in logomotor (speech motoric) response. Following on
from the second transplantation, he could recognize his parents,
interact with media, display limited vocal capacity, and turn and
sit up with support (Figure 5C). The last examination showed
that total CRS reached 15 points (Table 2) including 3 points in
arousability/attention, 4 points in motoric response, 2 points in
response to acoustic stimuli, 2 points in response to visual stimuli,
2 points in response to tactile stimuli, and 2 points in logomotor
(speech motoric) response.
Muscle spasticity reduced from level V to level II after
two transplantations. However, no significant changes on brain
MRI were observed 9 months after the first transplantation
(Figure 5D).
A summary of clinical parameters for the five patients are
presented in Table 2.
DISCUSSION
To our knowledge, this is the first publication using BMMNC
transplantation in the treatment of neurologic sequelea
after near-death drowning. BMMNC transplantation-related
adverse events were not observed, indicating the safety of
FIGURE 5 | The patient (case 5) before and after autologous BMMNC transplantation; (A) 2.5 months after the drowning before BMMNC transplantation, the patient
is in a VS. without awareness, no motor function, having tetraplegia, and exhibited muscle spasticity at level V. (B) Diffuse brain atrophy and abnormal signal at
bilateral putamen on brain MRI before transplantation (arrows). (C) Six months after the second transplantation, the patient could display limited vocal capacity and
turn and sit up with support. (D) There was no significant change in brain MRI after transplantations compared with before transplantation.
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BMMNC transplantation in patients with neurologic sequelae
after drowning.
In a neurologic long-term follow-up study of children that
suffered severe near-death drowning, the vegetative survivors
displayed no significant improvement after hospital discharge
(38). At present, there is no treatment for children in persistent
VS after drowning. Here, we found that BMMNC transplantation
clearly improved the major parameters of gross motor function,
cognition, and muscle spasticity in the five cases of VS after
drowning. Improvements in motor function occurred in all
patients. Two patients could sit up (case 1 and 4) and two
others (case 3 and 5) could stand up after transplantation. Muscle
spasticity was significantly reduced after transplantations which
contributed to improvements of motor function. Remarkable
improvements of cognition were observed in all five patients.
Especially, three patients (cases 1, 4, and 5) not only had
better communication but could also express words. Until
January 2020, all the BMMNC transplant recipients are in stable
conditions when followed up by telephone consultation.
Remarkably, in two patients with epilepsy, associated epilepsy
abated in one patient (case 4) and ceased completely in another
one (case 3) after BMMNC transplantation, thereby indicating
that BMMNC transplantation may ameliorate epileptic status
in patients with neurologic sequelae after drowning. To our
knowledge, this is the first report demonstrating a potential
role of BMMNC transplantation in ameliorating epileptic
status in patients with neurological complications after near-
death drowning.
Clinical improvements were observed in all five cases after
BMMNC transplantation. However, changes in brain tissue were
only observed in two patients after BMMNC transplantation
(cases 1 and 3), suggesting that functional recovery could bemore
obviously observed than morphologic improvement of the brain.
Autologous BMMNCs are a blend of undifferentiated cells,
including stem and progenitor cells that can be readily isolated
from bone marrow without ethical and technical concerns. For
the treatment of neurological deficits, it may be advised to use
BMMNCs as a heterogeneous cell mixture, in which some cells
may repair nerves through cell replacement, while other cells
may secrete different cytokines, growth factors, and extracellular
matrix molecules to assist in nerve repair and regeneration,
thereby supporting the growth of NSCs and inducing NSC
differentiation (39). In summary, cell therapy with autologous
BMMNC appeared to be safe and feasible for VS patients.
We observed potential effect of BMMNC transplantation on
functional recovery in the patients with neurologically devastated
by drowning, although the study was not designed with control
to draw that conclusion.
There are several limitations in this study. First, this was a
case series with small number of patients and designed without
controls. Indeed, there could be an isolated or added volumizing
effect in these patients. The small number of patients in this
study also makes it difficult to determine the risk factors related
to outcomes. Second, the patients had been recruited into
our hospital for BMMNC transplantation after receiving the
emergency care at the local hospitals, leading to the insufficient
clinical records related to drowning-related complications.
Third, two to four times of BMMNC transplantations have
been done based on the ability of the patients to sit up after
transplantation, and the first transplantation was performed at
different time points after the disease onset across patients,
whether a different in number of transplantation and time after
disease onset would have been associated with different outcomes
cannot be determined. Fourth, quantitative assessments to
evaluate the vegetative state, the gross motor function and
recovery of speech were not performed in this study. Together,
a prospective study with a greater cohort of participants and
quantitative functional assessment in a randomized controlled
trial should be performed to draw accurate and solid conclusions
about efficacy of BMMNC transplantation to improve patient’s
functions after near-death drowning.
CONCLUSIONS
Our results showed that BMMNC transplantation was safe and
could improve motor function and cognition of patients with
neurological sequelea after near-death drowning.
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